Multiple pharmacological therapies have been approved for malignant melanoma, including BRAF inhibitors (vemurafenib and dabrafenib), MEK inhibitors (trametinib), mAbs, such as Ipilimumab (mAb anti-CTLA4) and Pembrolizumab (mAb anti-PD1), and the oldest chemotherapy drug (dacarbazine). The gene discussed is BRAF; the disease is melanoma.